Research Institute

Hawaii Pacific Health

Down Syndrome

Thrombosis

Aneuploidy

COVID-19

Tremor

Necrosis

Arthritis

Trisomy

Parkinson Disease

Rheumatic Diseases

Apixaban

Suvecaltamide

Ramipril

Aspirin

Sequenom

Jazz Pharmaceuticals

Pfizer

University of Hawaii

Zimmer Biomet

Frank C Sciurba

Thomas L. Ortel

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tasks.

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

Hawaii Pacific Health | Research Institute

Site insights

Work at this site?

Active trials

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

Trial sponsors